Holen Sie sich die Stockscreener-App
182.09
0.08%
0.15
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot - Benzinga
Nvidia, Microsoft, Apple, Zillow, Biogen: What brokers said this week - Proactive financial news
Biogen shares could climb on Leqembi uptake – Jefferies - Proactive financial news
Biogen, Eisai Seek Japan Approval for Alzheimer's Drug At-Home Injection - MarketScreener
Jefferies Adjusts Price Target on Biogen to $210 From $190, Maintains Buy Rating - MarketScreener
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - Biogen
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - GlobeNewswire Inc.
Will Biogen Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly High Return Opportunities - moha.gov.vn
How Recent Developments Are Rewriting the Story for Biogen - Yahoo Finance
Total debt per share of Biogen Inc. – DUS:IDP - TradingView
Health Plans Defend Renewed Biogen MS Drug Scheme Suit - Law360
Biogen's $50 Million Immunology Power Move: Are Oral Peptides The Future? - Smartkarma
Wilson Sonsini Advises Dayra Therapeutics on Strategic Collaboration with Biogen Inc. - Wilson Sonsini
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - ACN Newswire
Avoiding Lag: Real-Time Signals in (BIIB) Movement - news.stocktradersdaily.com
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical DeclineJohnson & Johnson (NYSE:JNJ) - Benzinga
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline - TradingView
Biogen (BIIB) Advances Alzheimer's Treatment with FDA Submission - GuruFocus
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - PR Newswire
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership - MarketScreener
Why Biogen (BIIB) Is Up 7.4% After Announcing Dayra Immunology Collaboration and Pipeline Expansion - simplywall.st
Versant-backed start-up Dayra emerges with Biogen partnership: Deals Report - biocentury.com
BIIBLEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia - mx.advfn.com
Biogen Joins The Macrocycle Melee With Dayra Tie-Up - Citeline News & Insights
Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares. - Barron's
Biogen strikes deal with Versant-backed biotech to expand immune portfolio - BioPharma Dive
Key facts: Biogen shares rise 5% after Rybelsus trial failure; partners with Dayra - TradingView
How Do Investors Really Feel About Biogen Inc? - Benzinga
Health Care Stocks Edge Up As Biotech Shines And Eli Lilly Gets A Nod - Finimize
Dayra Therapeutics secures Biogen partnership and $70M before officially opening its doors - The Business Journals
Biogen partners with Dayra to develop oral macrocyclic peptides By Investing.com - Investing.com Nigeria
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data? - Sahm
Novo Nordisk’s Alzheimer’s Trials Were a Long Shot. Their Failure Is Still Hitting the Stock. - Barron's
Biogen and Dayra in deal over oral macrocyclic peptides - The Pharma Letter
Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact - Reuters
Biogen stock hits 52-week high at 177.37 USD By Investing.com - Investing.com Canada
Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies By Investing.com - Investing.com Canada
Biogen (BIIB) Partners with Dayra Therapeutics to Develop Oral M - GuruFocus
Biogen, Dayra Therapeutics Collaborate to Develop Oral Macrocyclic Peptides - MarketScreener
Novo Nordisk’s Alzheimer’s Trials Always Were a Long Shot. The Stock Is Falling Anyway. - Barron's
Biogen, Dayra Therapeutics Partner To Develop Oral Macrocyclic Peptides For Immunological Diseases - Nasdaq
Novo Nordisk shares plunge as oral semaglutide Alzheimer’s trial fails to show clinical benefit - TradingView
Biogen, Dayra Therapeutics to collaborate on developing oral macrocyclic peptides - MarketScreener
Biogen partners with Dayra to develop oral macrocyclic peptides - Investing.com
Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials - TradingView
Biogen, Dayra Therapeutics To Collaborate On Developing Oral Macrocyclic Peptides - TradingView
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions - Biogen
Biogen (Nasdaq: BIIB), Dayra to Develop Oral Macrocyclic Peptides for Immunology - Stock Titan
Biogen Reaches Research Deal With Dayra in Immunology Push - Bloomberg.com
Eli Lilly stock falls, Biogen rises after Novo’s Alzheimer’s trial failure - Investing.com Canada
Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis - MSN
Biogen (BIIB): Evaluating Valuation as Regulatory Wins and New Data Spark Investor Interest - simplywall.st
Does EMA Support for High Dose Nusinersen Redefine the Bull Case for Biogen (BIIB)? - Yahoo Finance
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Finviz
Piper Sandler Reiterates Biogen (BIIB) Neutral Recommendation - Nasdaq
Piper Sandler Reiterates Neutral Rating on Biogen (BIIB), Raises Price Target | BIIB Stock News - GuruFocus
Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer'sNovo Nordisk (NYSE:NVO) - Benzinga
Piper Sandler Adjusts Price Target on Biogen to $157 From $118, Maintains Neutral Rating - MarketScreener
Biogen Inc (BIIB.RTH) Stock Price, News & Analyst Forecast - eToro
Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix… - MarketScreener
0.30%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):